PJSC "International Medical Center for Processing and Cryopreservation of Biomaterials" increased its share in PJSC "Institute of Human Stem Cells" to 8.1% from 6.93%. The change occurred on June 21. This is stated in the message of the parties.
The Institute of Human Stem Cells (ISCH) is a Russian company founded in 2003. ISKCH is a strategic investor in the market of biomedical technologies, products and services. The company invests in assets related to the development and commercialization of innovative medicines, medical devices, new methods of genetic diagnostics and genetic research, as well as a number of other high-tech products and services in the field of biomedicine and healthcare. Among the products and services of the HSC group: Gemabank®, Neovasculgen®, Genetico®, Reprobank®, SPRS-therapy®. As part of the holding, there are companies at different stages of development (startups, seed stage, early growth companies, mature companies).
Consolidated revenue of the Institute of Human Stem Cells under IFRS for 2020 increased by 29.7% to 1.08 billion rubles. compared to a year earlier. Almost a third of the consolidated revenue came from the Genetico® Center's genetic research services, and 23% came from the Gemabank® personal biomaterial storage services. In 2020, revenues from the sale of Neovasculgen® amounted to 140.6 million rubles.